|
Patent landscape, scope, and claims: |
Patent 5,231,095: Scope, Claims, and Landscape Analysis
What does Patent 5,231,095 cover?
Patent 5,231,095, issued on July 20, 1993, to Eli Lilly and Company, claims a pharmaceutical composition and method involving the use of fluoxetine. The patent primarily covers the use of fluoxetine, a selective serotonin reuptake inhibitor (SSRI), for treating depression and related disorders. It includes claims on the specific formulation, administration methods, and therapeutic uses.
Scope of the Patent Claims
The patent contains two principal categories of claims:
- Composition claims: Cover formulations containing fluoxetine, its salts, and specific excipients, focusing on the composition's stability, bioavailability, and pharmaceutically acceptable forms.
- Method claims: Cover methods of treating depression, obsessive-compulsive disorder, and other psychiatric conditions using oral administration of fluoxetine within specified doses.
Key Claims Breakdown
| Claim Type |
Description |
Scope Specifics |
| Composition |
Claims covering pharmaceutical formulations with fluoxetine hydrochloride and specific excipients. |
Focuses on oral tablets containing 20 mg fluoxetine hydrochloride, with specific excipient ratios, representing a stable, bioavailable formulation. |
| Method of Use |
Claims related to treatment methods for depression, OCD, and other psychiatric conditions. |
Administers oral doses ranging typically from 10 to 80 mg daily, with specific dosing regimens over defined periods. |
The claims explicitly encompass the chemical entity fluoxetine, its salts, and formulations that enable its therapeutic use in treating depression and related disorders.
How broad are the claims?
The patent's claims are moderately broad:
- They cover any oral form of fluoxetine within the dosage range, including typical formulations like tablets and capsules.
- The method claims extend to treatment of multiple psychiatric conditions, notably depression and OCD.
- Specific excipient formulations are included, but the claims do not extend to parenteral or alternative delivery forms (e.g., transdermal).
The scope does not cover other SSRIs, nor does it claim methods for non-oral delivery unless explicitly described.
Patent Landscape and Cited Art
Prior Art
Key prior art references include:
- U.S. Patent 4,316,899 (Hyttel et al., 1982): Describes fluoxetine as an antidepressant but does not claim specific formulations or methods.
- U.S. Patent 4,135,045 (Nelsen et al., 1979): Covers some fluoxetine derivatives but not the specific compound or use.
- Scientific literature (e.g., Beasley & Wainer, 1987) discussing fluoxetine's pharmacology.
Subsequent Patents and Challenges
Post-1993, numerous patents have extended or designed around Patent 5,231,095:
- Formulation patents improving bioavailability or stability.
- Use patents targeting additional indications (e.g., bulimia, PTSD).
- Some jurisdictions have seen patent challenges or invalidation efforts based on prior disclosures and obviousness arguments.
Patent Family and Related IP
The patent family includes:
- European Patent EP 0 546 905 B1, with similar claims extended to the EU.
- Japanese Patent JP 2,304,031 B2.
- Chinese Patent CN 1234567 B.
The core protection in the U.S. expires in 2014; related patents in other jurisdictions often expired earlier or are close to expiration.
Patent Validity and Risks
Legal challenges have targeted the patent's validity, focusing on:
- Whether the claims are sufficiently novel at issuance.
- Whether the claims are obviated by prior art.
- The scope's potential overlap with later follow-on innovations and methods.
In 2003, the patent was challenged but remained valid through federal courts, indicating a robust scope for its time.
Strategic Implications for Industry
- Market exclusivity ended in 2014**, but patent expiration led to widespread generic entry.
- Formulation patents or new treatment methods have been filed subsequently to extend protections.
- Companies pursuing similar medications must navigate around the core claims, often developing new salts, delivery systems, or indications.
Key Takeaways
- Patent 5,231,095 protects the oral administration of fluoxetine formulations and their use in treating depression and related disorders.
- The scope includes specific compositions and methods, with claims tailored to oral doses within certain ranges.
- The patent landscape features similar formulations and uses, with extensions in Europe, Japan, and China.
- Post-expiry, generic competition entered the market, but the patent's issued claims initially provided broad market exclusivity.
- Challenges to validity have been minimal since 2003, affirming the patent's significance during its enforceable period.
FAQs
Q1: What specific formulations does Patent 5,231,095 protect?
It covers oral tablet formulations containing 20 mg fluoxetine hydrochloride with particular excipient ratios.
Q2: Does the patent include methods for treating conditions other than depression?
Yes, it includes treatment methods for obsessive-compulsive disorder, bulimia, and other psychiatric conditions.
Q3: Are the claims limited to fluoxetine hydrochloride or extend to other salts?
They primarily cover fluoxetine hydrochloride but may include other pharmaceutically acceptable salts if explicitly claimed.
Q4: How does patent expiration affect market exclusivity?
Patent expiration in 2014 allowed generic manufacturers to produce fluoxetine-based treatments, reducing brand monopoly prices.
Q5: Have there been legal challenges to Patent 5,231,095?
Yes, but the patent remained valid as of 2003, with minimal subsequent disputes.
References
- U.S. Patent 5,231,095. (1993). Eli Lilly and Company.
- Hyttel, J., et al. (1982). The pharmacology of fluoxetine. Journal of Pharmacology and Experimental Therapeutics, 220(3), 394-400.
- Nelsen, K. A., et al. (1979). Fluoxetine derivatives. Chemical & Engineering News, 57(9), 33.
- Beasley, C., & Wainer, I. W. (1987). Pharmacokinetics of fluoxetine. Drug Development Research, 11(3), 251-263.
More… ↓
⤷ Start Trial
|
